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Abstract: Salmonellosis is among the most reported foodborne illnesses in the United States. The
Salmonella enterica Typhimurium DT104 phage type, which is associated with multidrug-resistant
disease in humans and animals, possesses an ADP-ribosylating toxin called ArtAB. Full-length artAB
has been found on a number of broad-host-range non-typhoidal Salmonella species and serovars.
ArtAB is also homologous to many AB5 toxins from diverse Gram-negative pathogens, including
cholera toxin (CT) and pertussis toxin (PT), and may be involved in Salmonella pathogenesis, however,
in vitro cellular toxicity of ArtAB has not been characterized. artAB was cloned into E. coli and
initially isolated using a histidine tag (ArtABHIS) and nickel chromatography. ArtABHIS was found
to bind to African green monkey kidney epithelial (Vero) cells using confocal microscopy and to
interact with glycans present on fetuin and monosialotetrahexosylganglioside (GM1) using ELISA.
Untagged, or native, holotoxin (ArtAB), and the pentameric receptor-binding subunit (ArtB) were
purified from E. coli using fetuin and D-galactose affinity chromatography. ArtAB and ArtB metabolic
and cytotoxic activities were determined using Vero and Chinese hamster ovary (CHO) epithelial
cells. Vero cells were more sensitive to ArtAB, however, incubation with both cell types revealed
only partial cytotoxicity over 72 h, similar to that induced by CT. ArtAB induced a distinctive
clustering phenotype on CHO cells over 72 h, similar to PT, and an elongated phenotype on Vero cells,
similar to CT. The ArtB binding subunit alone also had a cytotoxic effect on CHO cells and induced
morphological rounding. Results indicate that this toxin induces distinctive cellular outcomes.
Continued biological characterization of ArtAB will advance efforts to prevent disease caused by
non-typhoidal Salmonella.
Keywords: Salmonella Typhimurium; AB5 toxin; ArtAB
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Key Contribution: We present a rapid glycan-based method for affinity purification of ArtAB; a
toxin produced by Salmonella Typhimurium DT104; and ArtB; its receptor-binding subunit from
E. coli. The activity of purified ArtAB and ArtB was characterized on two epithelial cell lines. ArtAB
triggers cellular cytotoxicity and morphologic changes consistent with those induced by homologous
ADP-ribosylating AB5 -type toxins. ArtB has cellular activity that is distinct from that of the holotoxin.
The purification method and characterization of cellular activity presented here will support future
investigations into the contribution of ArtAB to Salmonella pathogenicity.
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1. Introduction
Salmonellosis, caused by the Gram-negative bacteria Salmonella, is one of the most
common foodborne diseases in the world [1,2]. Non-typhoidal serovars of Salmonella (NTS)
generally cause self-limiting gastroenteritis. However, they can cause systemic infections
and are increasingly antibiotic resistant, resulting in an estimated 1.35 million illnesses
and 420 deaths per year in the U.S. [3]. Salmonella has a complex taxonomy and is a
diverse human and animal pathogen. Salmonella enterica, one of two overall species, has
six subspecies. One subspecies, enterica (Salmonella enterica, subsp. enterica), contains over
2500 serovars. The NTS within this subspecies are pathogenic to a broad range of vertebrate
species, including humans and human food sources such as cattle, swine, and poultry [4,5].
This is in contrast to the narrow host range of the human typhoidal serovars S. Typhi and
S. Paratyphi, which cause severe invasive disease with a high mortality rate but with lower
numbers of cases globally.
The virulence factors contributing to Salmonella enterica pathogenicity are numerous
and include well-characterized secretion systems, adhesins, and capsular polysaccharides [6]. In the mid-1990s, the NTS phage-type S. Typhimurium DT104 became the
predominant strain infecting livestock and was commonly associated with human hospitalization [7]. DT104 is highly antibiotic resistant and virulent, however, studies have failed
to fully identify the mechanism of increased virulence [8,9]. In 2005, DT104 was found to
contain an enterotoxin, with homology to AB5 -type toxins, called artAB [10]. AB5 -type
toxins are potent virulence factors produced by many pathogenic Gram-negative bacteria.
They are composed of a pentameric B subunit (B5 ), which binds to host cell-surface receptors, and an A subunit, which becomes catalytically active inside the host cell. AB5 -type
toxins contribute to the development of infectious diseases associated with altered ion flow
across membranes and disruption of epithelial barrier function [11,12]. artAB has since
been identified on a number of additional S. enterica serotypes, and on S. bongori, and has
been determined to be a secreted ADP-ribosylating toxin with homology to the AB5 -type
toxins cholera toxin (CT) and pertussis toxin (PT) [13–15].
CT and PT are two of the most well-characterized bacterial toxins. CT, produced
by Vibrio cholerae, is folded into a holotoxin in the bacterial periplasmic space prior to
secretion and interaction with the host cell. CT becomes activated when the active subunit
(CTA) is proteolytically cleaved, or nicked, by a host serine protease [16]. After secretion,
the binding subunit (CTB) binds to monosialotetrahexosylganglioside (GM1), which is
expressed on the surface of intestinal epithelial cells. This interaction triggers retrograde
endocytosis of the CT holotoxin to the endoplasmic reticulum (ER). In the ER, CTA becomes separated from CTB and moves into the host cell cytoplasm where it binds to, and
constitutively activates, the Gαs protein through ADP ribosylation. Gαs activates adenylate
cyclase (AC), causing an increase in cyclic adenosine monophosphate (cAMP), which leads
to dysregulation of cellular ion channels and, ultimately, secretory diarrhea. PT, produced
by Bordetella pertussis, is a homologous AB5 toxin with mechanistic similarities. However,
the B subunit is structurally distinct and binds to a broader range of sialylated and nonsialylated N-linked glycans [17]. PT’s active subunit (PTA) has a distinct ADP-ribosylation
target; it inactivates Gαi . Despite having different ADP-ribosylation targets, the outcome is
similar; AC is activated, and cellular cAMP is increased. CT and PT are also both components of licensed safe and effective vaccines [18,19]. The ability to chemically or genetically
detoxify CT, PT, and other AB5 toxins while retaining antigenicity and immunomodulatory characteristics has supported their use as vaccine adjuvants and molecular tools for
cellular delivery [20–23]. Thus, in addition to improving the understanding of Salmonella
pathogenesis, the study of the cellular activities of ArtAB and ArtB is relevant to vaccine
design and development.
While the ADP-ribosylation activity and in vivo lethality of ArtAB have been reported,
the cellular activity, including the cytotoxicity and morphologic activities, of ArtAB and its
receptor-binding subunit, ArtB, have not been previously described [14,15]. In addition,
despite numerous studies on various AB5 -type toxins, few studies have directly compared
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the cellular effects of these toxins. The goals of this study were to develop a rapid method
of purification of ArtAB and ArtB from E. coli and to use the purified proteins to identify
a reproducible and consistent cellular phenotype in vitro. Results indicate that ArtAB
induces a slow cytotoxic response and characteristic changes in cellular morphology,
similar to the responses induced by CT and PT. ArtB alone may also be cytotoxic, and it
induces a distinct morphologic response. These studies will promote further structural
and functional characterization of ArtAB and improve our understanding of its role in
Salmonella pathogenesis.
2. Results
2.1. Phylogenetic Analysis of AB5 Toxin Subunits
Phylogenetic trees were constructed with MEGA using the maximum-likelihood
method to align the amino acid sequences of S. Typhimurium DT104 ArtA and ArtB to
those of AB5 toxin subunits from other Gram-negative bacteria [24]. As shown in Figure 1A,
the enzymatically active ArtA subunit is most closely related to ArtA from S. Worthington
and S. bongori, as described [14]. S. Typhimurium DT104 ArtA is also related to the active
subunit of an AB5 toxin from E. coli (68% identity), which has been named previously as
both pertussis-like toxin (EcPltA) and ArtA [25,26]. S. Typhimurium DT104 ArtA also has
homology (58% identity) to S. Typhi PltA, an active subunit of the S. Typhi pertussis-like
toxin (Plt). Plt is also commonly referred to as typhoid toxin (TT). Plt/TT is a unique A2 B5
toxin that utilizes two active subunits: PltA and CdtB. CdtB has nuclease activity and low
homology (18% identity) to S. Typhimurium DT104 ArtA [27]. ArtA also shows significant
relatedness to a pseudogene found in both S. Typhi and S. Montevideo (90% identity over a
99 amino acid central region), that is unlikely to be expressed [28]. Lastly, ArtA is distantly
related to the active subunits of PT (PTA S1; 28% identity), an uncharacterized AB5 toxin
from Yersinia (YtxA; 26% identity), E. coli type IIa heat-labile enterotoxin (LTIIaA; 24%
identity), and CT (CTA; 23% identity).
Figure 1B shows the phylogenetic relationships of S. Typhimurium DT104 ArtB, which is
most closely related to the B subunits from S. Worthington and S. Typhi (85 and 73% identity,
respectfully). An uncharacterized subtilase cytotoxin-like binding subunit (SubB2) from
E. coli shows 60% identity to S. Typhimurium DT104 ArtB, while the more well characterized
E. coli subtilase cytotoxin B (SubB), which has been shown to promote the binding to sialylated
glycans, has only limited homology (26% identity) [29]. S. Typhimurium DT104 ArtB has
low homology to the binding subunit of Plt/TT (PltB; 30% identity), supporting previous
glycan array studies that revealed ArtB’s specificity for sialylated glycans that are distinct
from those that bind with PltB [30,31]. S. Typhimurium ArtB has more limited homology to
the well-characterized binding subunit of CT (CTB; 24% identity), as well as to the likely AB5
toxins from S. arizonae (SalB; 29% identity), S. bongori (ArtB; 26% identity), and Yersinia pestis
(YrpB; 24% identity). PT has four distinct binding subunits, and ArtB has some limited
homology to the second (PtxB S2; 15% identity). A ribbon diagram of the predicted structure
of ArtAB was constructed using I-TASSER and is shown in Figure 1C [32,33].
The artAB-like operons from a non-DT104 S. Typhimurium isolate, as well as S. Typhi,
S. Paratyphi, and S. Choleraesuis were analyzed by PCR and compared to four human
clinical S. Typhimurium DT104 isolates using flanking primers of the artAB region (Supplementary Figure S1A). The smaller amplicons of 957 and 954 bp, respectively, support
the presence of the homologous artB gene and a truncated pseudogene which contains a
deletion within artA (Supplementary Figure S1B).
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2.2. Purification and Binding of ArtABHIS
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S. Typhimurium DT104 artAB was cloned into the pBAD18 expression vector with a
hexa-histidine tag (6XHIS) introduced at the C-terminus of the B subunit to construct
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pBM003 (Supplementary Figure S2A). Holotoxin was purified using cobalt affinity
chromatography. Purified toxin with the expected molecular weights of processed (signal
sequence removed) ArtA (∼25.6 kDa) and ArtB-HIS (∼14.2 kDa) were confirmed using
SDS-PAGE, western blotting (Supplementary Figure S2B), and protein sequencing by
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staining within the cell that was above background levels (Figure 2A).
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2.3. Cloning and Glycan Affinity Purification of ArtAB and ArtB
To begin to assess the binding specificity of ArtABHIS, we performed ELISA-based
binding assays with purified ArtABHIS. Since CT is known to have a strong binding affinity
for GM1 and some affinity for the sialylated glycans found on the blood protein fetuin, we
performed a comparative assay with these two receptor molecules using anti-6XHIS (for
ArtAB) or anti-CT (for CT) antibodies [34,35]. ArtABHIS bound to fetuin with consistently
higher titers than to GM1 (Figure 2B,C), while CT bound to GM1 with higher average titers
(Figure 2C).
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kDa. Despite evidence that ArtAB binds less well to GM1, native ArtAB isolated using
immobilized D-galactose was of markedly higher purity than native ArtAB isolated on
fetuin, and had higher purification efficiency, with close to 6 mg of protein purified from
one liter of culture (versus 2–4 mg/liter using fetuin). SDS-PAGE of fetuin-purified ArtAB,
6 of in
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and sometimes D-galactose-purified ArtAB, revealed a third peptide that was similar
molecular weight to ArtA (Figure 3B, lanes 3–4). All peptide bands, including the two
ArtA bands that purified near 25 kDa, were sequenced by LC–MS mass spectrometry to
confirm identity (Supplementary Figure S2D, Supplementary Table S2). The larger (∼26
2.3. Cloning and Glycan Affinity Purification of ArtAB and ArtB
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As determined from ArtABHIS binding assays, ArtAB also binds to ganglioside
GM1. GM1 contains D-galactose moieties, thus ArtAB holotoxin was also purified using D-galactose affinity chromatography. Purified ArtAB was confirmed with SDS-PAGE
(Figure 3C), and unboiled samples supported an AB5 compostion of approximately 93 kDa.
Despite evidence that ArtAB binds less well to GM1, native ArtAB isolated using immobilized D-galactose was of markedly higher purity than native ArtAB isolated on fetuin,
and had higher purification efficiency, with close to 6 mg of protein purified from one
liter of culture (versus 2–4 mg/liter using fetuin). SDS-PAGE of fetuin-purified ArtAB,
and sometimes D-galactose-purified ArtAB, revealed a third peptide that was similar in
molecular weight to ArtA (Figure 3B, lanes 3–4). All peptide bands, including the two ArtA
bands that purified near 25 kDa, were sequenced by LC–MS mass spectrometry to confirm
identity (Supplementary Figure S2D, Supplementary Table S2). The larger (~26 kDa) and
smaller (~23 kDa) peptides were both confirmed to be ArtA, indicating that the A subunit
may also be proteolytically cleaved, or nicked, similar to that observed for PT [37].
Purification of the ArtB binding subunit alone was also completed using D-galactose
affinity chromatography. The plasmid pLC001 (Figure 3D), was constructed to express
S. Typhimurium DT104 ArtB alone from E. coli. D-galactose-isolated ArtB was observed
using SDS-PAGE and unboiled samples were consistent with a pentameric structure of
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metabolic activity dropped to an average of 90% of vehicle control (lowest activity was
85.8% of control with 2 μg at 48 h). Cytotoxicity assays on CHO cells treated with
holotoxins were consistent with these results, with significant differences between
holotoxin-treated and vehicle-treated cells at all time points (Figure 4B). Vero cells
7 of 19
revealed a higher sensitivity to ArtAB with metabolic activity dropping to an average
of
80% of vehicle control (lowest activity was 77% of control with 10 μg at 72 h), and
significant differences between holotoxin-treated and untreated cells at 48 and 72 h
approximately
67 kDa
3E). Purified
ArtB
was also
confirmed
masstime
spectrometry
(Figure
4C). Vero
cell (Figure
cytotoxicity
reached
greater
than
50% atbylater
points, with
(Supplementary
Table
S2).
significant differences between holotoxin-treated and untreated cells at 24, 48 and 72 h
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2.4. Cellular Activity of ArtAB
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The cellular activity of purified ArtAB was determined using two epithelial cell lines.
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μg of protein
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Figure 4. Metabolic and cytotoxic activity of ArtAB and CT on epithelial cells in vitro. (A) Resazurin metabolic assays and
(B) crystal violet cytotoxicity assays on CHO cells, and (C) resazurin and (D) crystal violet assays on Vero cells. Purified
ArtAB was incubated with cells at 2, 5, or 10 µg per 200 µL well for 4, 24, 48, or 72 h at 37 ◦ C. Results are reported as the
percent of vehicle control activity, and toxin groups at each time point are compared to media alone (also reported as the
percent of vehicle control activity) using a one-way analysis of variance (ANOVA) and Tukey’s HSD. Stars above the bar
indicate a significant difference from media alone at that time point (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001).

On CHO cells, metabolic assays at early time points indicated that ArtAB had no effect,
or potentially increased the metabolic activity (Figure 4A). At later time points, metabolic
activity dropped to an average of 90% of vehicle control (lowest activity was 85.8% of
control with 2 µg at 48 h). Cytotoxicity assays on CHO cells treated with holotoxins were
consistent with these results, with significant differences between holotoxin-treated and
vehicle-treated cells at all time points (Figure 4B). Vero cells revealed a higher sensitivity to
ArtAB with metabolic activity dropping to an average of 80% of vehicle control (lowest ac-
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tivity was 77% of control with 10 µg at 72 h), and significant differences between holotoxin8 of 19
treated and untreated cells at 48 and 72 h (Figure 4C). Vero cell cytotoxicity reached greater
than 50% at later time points, with significant differences between holotoxin-treated and
untreated cells at 24, 48 and 72 h (Figure 4D). There was no significant dose-dependent
Figure 4. Metabolic and cytotoxic activity of ArtAB and CT on epithelial cells in vitro. (A) Resazurin metabolic assays and
effect of ArtAB for either cell type in the range used (2 µg to 10 µg of toxin) in these assays.
(B) crystal violet cytotoxicity assays on CHO cells, and (C) resazurin and (D) crystal violet assays on Vero cells. Purified
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On Vero cells, all ArtAB treatments triggered varying levels of destruction of the cells
with a less distinct phenotype. However, Vero cells treated with ArtAB demonstrated
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On Vero cells, all ArtAB treatments triggered varying levels of destruction of the cells
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2.5. Cellular Activity of ArtB
2.5.
Cellular Activity of ArtB
The metabolic and cytotoxic activity of ArtB was determined using the same epithelial
The metabolic and cytotoxic activity of ArtB was determined using the same
cell lines. Similar to holotoxin, ArtB induced an increase in metabolic activity at early time
epithelial cell lines. Similar to holotoxin, ArtB induced an increase in metabolic activity at
points that was significant over media alone for the lower 2 µg concentration (Figure 7A).
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dependent effect on both metabolism and cell survival at all time points. Visual
assessment of cells by microscopy indicated that ArtB alone induces morphologic changes
on CHO cells that are distinct from those induced by holotoxin. Treatment with ArtB may
have prevented adherent CHO cells from forming paracellular junctions, resulting in the
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vehicle-treated cells alone (data not shown).
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3. Discussion
We report the glycan affinity purification and cellular activity of S. Typhimurium
ArtAB toxin as well as that of the ArtB binding subunit alone. The method of using Dgalactose affinity for purification was found to be rapid and efficient and was used to
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3. Discussion
We report the glycan affinity purification and cellular activity of S. Typhimurium
ArtAB toxin as well as that of the ArtB binding subunit alone. The method of using
D -galactose affinity for purification was found to be rapid and efficient and was used to
purify native (untagged) ArtAB and ArtB to high concentrations. The cellular metabolic,
cytotoxic, and morphologic effects were identified on two epithelial cell lines that have
been commonly used to characterize bacterial toxins.
Native toxin purified from E. coli is consistent with the expected size and sequence of
toxin purified directly from S. enterica Typhimurium DT104, enabling large scale protein
purification to be performed in lower biohazard laboratory conditions. Unidentified
differences in purification conditions resulted in the occasional production of a lowermolecular-weight peptide that was confirmed by LC–MS to also be ArtA (Supplementary
Figure S2D), providing evidence that ArtA contains a proteolytic cleavage site. An A1
subunit of 22–23 kDa indicates that ArtA may contain a proteolytic processing site, similar
to that reported for PT and CT [41,42]. The cleavage of CT is required for maximal activation
and cellular activity. The enzyme for CT cleavage is a host-derived serine protease that
generates a 22 kDa A1 subunit which remains connected to the A2 subunit via a disulfide
bond [16]. Similar to CT, processing of PT is predicted to occur within a protease-sensitive
loop of the S1 subunit near the C-terminus. The PT S1 subunit is thought to remain
connected to the holotoxin through a disulfide bond; located between residues C41 and
C201 [43]. In vitro, PT S1 cleavage results in a 22 kDa S1 subunit (from the 26 kDa fulllength S1) and enhances ADP ribosylation [41]. While reduction of the disulfide bond and
ATP-binding are both required for PT activity, proteolytic processing has not been found to
be essential for cellular activity [44,45]. Our results indicate that the A subunit of ArtAB
may be cleaved. However, current efforts have not identified a specific cleaving enzyme
or determined if cleavage is required for activation. ArtA does contain cysteine residues
(C38 and C198) in primary structure locations similar to those of PT, which may hold the
cleaved strands of the A subunit together into the holotoxin structure.
Purification of hexa-histidine-tagged ArtAB resulted in the consistent production
of two lower-molecular-weight bands under 15 kDa (Supplementary Figure S2C). Both
peptides were confirmed by LC–MS to be ArtB, and the smaller band was untagged as
determined by Western blot. We hypothesize that the location of the HIS-tag results in
steric hindrance and may prevent pentamer formation with fully tagged monomers. While
this toxin could be purified to high concentration, the location of the tag may reduce
normal receptor binding and/or prevent glycan binding at a second site, which has been
determined to be located on the outside of the pentamer [30]. Cell trafficking and receptorbinding assays reported here with the ArtABHIS protein are preliminary, and there is a
possibility of non-specific interactions using α-HIS. Thusfuture studies will focus on the
use of native toxin for these assays.
Cellular assays indicated that purified ArtAB induced a slow and limited cytotoxicity
that is similar to that of CT. These studies revealed an approximate 15% (CHO) to 50%
(Vero) decline in cell viability compared to vehicle-treated cells over 72 h. In dividing
cells, alamarBlue™, or resazurin dye, is reduced to resorufin by aerobic respiration, so this
assay is an indicator of metabolic activity rather than a comparison of live-versus-dead
cells. Resazurin assays confirmed the decline in cell viability at later time points. Notably,
we did not observe concentration-dependent cellular activity using a limited range of
concentrations (2, 5, or 10 µg per 200 µL treatment). In addition, by 72 h, some cells in
all cultures were able to recover from, or were initially resistant to, toxin treatment such
that a detectable recovery of individual cells, as well as the population as a whole, could
be observed. This is consistent with a bi-modal response to toxins that are able to bind to
more than one cellular receptor, as has been described [46,47]. Binding to a sub-optimal
host glycan may promote a lower concentration of toxin reaching the host cytosol and
thus a population of cells that are not fully intoxicated. This effect may also explain why
concentration-dependent responses cannot be detected unless concentrations cover a larger
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range. Future studies can assess a broader range and use assays to detect individual cell
responses within a population.
The cellular aggregation and morphological changes observed in this study are consistent with a previous assay of the Salmonella supernatant activity on CHO cells and the
identification of ADP-ribosylation activity [15]. These studies indicate that the observed
cellular changes are induced by active toxin-stimulated increases in cAMP and that they
are dependent upon specific active subunit–receptor interactions [48,49]. CT is well known
to induce elongation in CHO cells and rounding in Y1 adrenal gland cells and has been reported to cause increased cellular adherence [50–52]. It has also been reported that adhesion
molecules such as Thrombospondin-1 and Integrin-β1 are upregulated when monocytes
are treated with CT [53]. In contrast, when treated with PT, CHO cells, which normally
grow in uniform monolayers, exhibit a distinct clustering phenotype [54]. This is similar to
our observations with ArtAB and supports the hypothesis that this toxin also induces a
receptor-specific cellular activity that involves cytoskeletal rearrangement and changes in
expression of adhesion molecules [55]. Two novel pertussis-toxin-like toxins from E. coli
have been reported to induce both elongation and clustering of CHO cells [56]. These
studies futher utilitize CHO morphology as a sensitive bioassay to determine toxin titer and
identify potential receptors. The cellular phenotypes identified for ArtAB could similarly
be used to assay toxin concentrations and identify receptors using mutant cell lines.
Somewhat surprisingly, the ArtB subunit alone also had cytotoxic activity on CHO
cells, killing up to 60% of cells after 72 h at higher concentrations, as determined by crystal
violet assay. The morphology of CHO cells was also affected by ArtB. We observed a
distinct rounding of individual adherent cells, possibly indicating that ArtB is preventing
the formation of paracellular junctions. These results indicate that receptor-binding and/or
internalization of the B subunit alone induces significant cellular activity and may be
relevant in bacterial pathogenicity. This has not been described for CTB but has been
described for Shiga toxin B subunit [57]. artB is also present on typhoidal Salmonella
serovars and is associated with an artA pseudogene that is likely not expressed. Recently
S. Typhi artB has been found to be present on many additional Salmonella serovars and may
provide an alternative binding subunit for Typhi Toxin (TT) [28]. artB of S. Typhi was also
determined to be expressed, especially under conditions that may occur inside of host cells.
While ArtB of S. Typhi has only 74% identity to ArtB of S. Typhimurium DT104 (Figure 1),
these studies support the important role that the binding subunit alone may play in
Salmonella pathogenesis. The crystal structure and glycan binding array of S. Typhimurium
ArtB has been determined using a purified 6XHIS subunit from E. coli [30]. These studies
indicated that ArtB likely binds to terminal Neu5Ac and Neu5Gc sialylated glycans, both
of which can be found on bovine fetuin. GM1 is a monosialylated glycosphingolipid with
an internal Neu5Ac, and a terminal D-galactose. D-galactose agarose affinity purification
has long been established as a rapid and efficient method of purifying CT [58]. The ability
of ArtAB to be efficiently purified using D-galactose indicates that this toxin also binds
well to this terminal glycan and likely has a broad receptor specificity, similar to that of
PT [17]. The binding to Neu5Gc also supports the importance of this toxin in animal disease,
as humans do not synthesize this glycan. In these studies, we identified the binding and
internalization of ArtABHIS into Vero cells, and activity on Vero and CHO cells. Future
studies will assess the activity of ArtAB on additional cell types, as well as the binding to
other glycoproteins/glycolipids, to help narrow potential cellular receptors, define target host
cells and explore the utility of this toxin or receptor as a potential animal or human vaccine.
Both cell types incubated with ArtAB, and CHO cells incubated with ArtB, showed a
potential increase in metabolic activity at early time points. This response was significant
for ArtB on CHO cells and corresponded to an increase in cell number. The metabolic
increase is consistent with the use of CT as an adjuvant that enhances the activation and
proliferation of immune cells, as well as other cell types, at low concentrations [59–61].
This burst may also reflect the initiation of programmed cell death and the production of
extracellular membrane vesicles, or exosomes, in response to intoxication. CT has been
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found to induce apoptosis in different cell types [62,63]. Vero cells in these studies were more
sensitive to toxin and also produced a large number of exosomes in response to both CT and
ArtAB. Exosomes can be induced as a survival mechanism to rapidly rid the cell of toxin or B
subunit, as has been shown for S. aureus α-toxin [64]. We hypothesize that the mechanisms
behind cell death and cellular defenses to ArtAB are similar to that of CT, and this toxin may
induce apoptosis in some cell types. These activities will continue to be explored.
4. Conclusions
We report a method of rapid native ArtAB and ArtB purification based on glycan
affinity and identify toxin binding and cellular activity in vitro. The availability of ArtAB
and ArtB in native form will promote a varied set of downstream applications for the
continued biological characterization of this toxin. Cellular assays can be used to further
assess the expression of ArtAB from pathogenic Salmonella and the extent of ArtAB’s
contribution to virulence and clinical outcomes in a broad host range. The structure and
functionality of ArtAB can also be further defined, which will advance our understanding
of bacterial AB5 toxins, as well as support efforts to prevent or treat salmonellosis in
humans and animals. The identification of methods to reduce or eliminate Salmonella in
agriculturally important animals is a priority, and will help to reduce animal mortality,
increase production, and prevent transmission to humans.
5. Materials and Methods
5.1. Bacterial Strains and Growth Conditions
Salmonella enterica Typhimurium phage-type DT104, isolates SC09039, SC09068, SC09073,
SC09074, are human gastroenteritis clinical isolates obtained from the Idaho Bureau of Laboratories (Boise, ID) and used for genomic DNA preparation, artAB PCR, and sequencing.
The isolate SC09039 was used for artAB and artB cloning and purification. Human clinical
S. Typhi, S. Paratyphi A and S. Choleraesuis genomic DNA was supplied by the Idaho
Bureau of Laboratories for PCR. E. coli TE1 [65] was used for cloning, and E. coli ClearColi®
BL21(DE3) (Lucigen, Madison, WI) was used for protein expression and toxin isolation.
For genomic DNA preparation, bacterial cells were grown overnight in Luria Broth (LB) at
37 ◦ C. For plasmid preparation, cells were grown in LB plus 25 µg/mL chloramphenicol
(CM) and 0.02% glucose overnight at 37 ◦ C.
5.2. Phylogenetic Analysis and Predicted Tertiary Structure of AB5 Toxin Subunits
Sequence alignments and evolutionary analysis were completed using MEGA 7 [24]. A
rooted dendrogram of exhaustive pairwise AB5 toxin alignments of 20 sequences (A subunits)
or 19 sequences (B subunits) was constructed using the maximum-likelihood method based
on the JTT matrix-based model [66]. Protein sequences were retrieved from the National Center for Biotechnology Information NCBI. Available online: https://www.ncbi.nlm.nih.gov/
(accessed online on 22 May 2020) and accession numbers are provided in Supplementary
Table S1. The I-TASSER server was used to visualize predicted tertiary structures of ArtA
and ArtB using the model templates: E. coli SubB [29] for ArtB and E. coli PltA [25] for
ArtA [32,33].
5.3. Construction of ArtABHIS, ArtAB, and ArtB Expression Plasmids
The artAB gene was amplified from S. Typhimurium DT104 SC09039 by polymerase
chain reaction (PCR) from isolated genomic DNA using the 070pr forward primer (GATCCTCGCTAGCGTTT CTGTAGGAGGGTGTATG) and the 071pr reverse primer (GTACCAGAAGCTTTTAGTGATGGTGATGGT GATGGTTTGGCAACGTAGGTCCC), that introduces a 6XHIS. The amplified product was cloned into the pBAD18CM vector (ATCC, Manassas, VA) and transformed into E. coli TE1 for confirmation prior to introduction into the
endotoxin-free E. coli strain ClearColi® (Lucigen, Madison, WI) for protein production. The
resulting plasmid (Supplementary Figure S2A) was designated pBM003. For pBM006 construction (Figure 3A), the artAB gene was amplified from DT104 SC09039 using the forward
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primer 070pr and the reverse primer 099pr (GCGCCAGAAGCTTGAAATATTTAGTTTGGCAAC GTAG). The amplified product was similarly cloned into pBAD18CM and transformed into E. coli TE1 and ClearColi® . To clone artB alone into pLC001 (Figure 3D), the
forward primer, 198pr (GCCTAGGGCTAGCGGTAAATATTTTAGGAGTGG), which contains a modified ribosome-binding site, and the reverse primer, 099pr, were used to amplify
artB from S. Typhimurium SC09039, and the resulting product was cloned into pBAD18CM
and purified from ClearColi® . The sequences of pBM003, pBM006, and pLC001 were
confirmed by sequencing through forward and reverse junctions (Idaho State University
Molecular Research Core Facility, Pocatello, ID).
5.4. Expression and Purification of ArtABHIS, ArtAB, and ArtB from E. coli
ClearColi® transformed with plasmid pBM003 was cultured in LB containing 25 µg/mL
CM and 0.02% glucose overnight at 37 ◦ C. Overnight cultures were then transferred to
Terrific Broth (TB) with 25 µg/mL CM and shaken at 37 ◦ C. When the culture reached an
optical density between 0.6 and 0.9, protein expression was induced with 0.2% L-arabinose.
Induced cultures were shaken overnight at 37 ◦ C. After centrifugation, the harvested cells
were resuspended and protein was extracted from the periplasmic space by the addition
of 1 mg/mL polymyxin B. The cell extract was collected by centrifugation and phenylmethylsulfonyl fluoride (PMSF) was added at 100 µM. The extract was purified using
cobalt affinity column chromatography (HisPur™ Cobalt Resin, Thermo Fisher Scientific,
Waltham, MA, USA) per the manufacturer’s instructions. Fractions were collected in 1.5 mL
aliquots and confirmed using SDS-PAGE. Fractions containing ArtABHIS were pooled
and dialyzed using 12,000 Da-molecular-weight cutoff (MWCO) dialysis cassettes (Slide-ALyzer™, Thermo Fisher Scientific) against 1× PBS + 5% glycerol at 4 ◦ C overnight with
one buffer change after 6 h. Dialyzed sample was further concentrated using a 50,000 Da
MWCO concentration filter (Amicon Ultra-15, Merck Millipore Ltd., Thermo Fisher Scientific). Molecular weight and purity were confirmed using SDS-PAGE and Western blot with
α-HIS6 primary (1:2500 Abcam, Cambridge, MA, USA) and HRP-conjugated goat α-rabbit
IgG secondary (1:5000, Promega, Madison, WI, USA) antibodies. Protein concentration
was determined by bicinchoninic acid (BCA) protein assay (Pierce™ BCA Protein Assay
Kit, Thermo Fisher Scientific) using bovine serum albumin (BSA) as a standard.
For purification of native ArtAB and native ArtB, E. coli ClearColi® was transformed
with plasmid pBM006 or pLC001and induced protein isolated from the E. coli periplasmic
space as above for pBM003. The extract was purified using immobilized D-galactose
affinity column chromatography (Pierce™ D-galactose Agarose, Thermo Fisher Scientific),
as described [67]. Column equilibration and washing were performed using 1× PBS,
and elution was performed using 1 M D-galactose (ACROS Organics™). Fractions were
collected in 1.5 mL aliquots and confirmed with SDS-PAGE. Fractions containing ArtAB or
ArtB were pooled and dialyzed in 12,000 Da MWCO dialysis cassettes (Slide-A-Lyzer™,
Thermo Fisher Scientific) against 1× PBS + 5% glycerol at 4 ◦ C overnight with one buffer
change after 6 h. Dialyzed samples were concentrated using a 50,000 Da MWCO disposable
filter (Amicon Ultra-15, Merck Millipore Ltd., Thermo Fisher Scientific). Molecular weight
and purity were confirmed with SDS-PAGE, and protein concentration was determined by
BCA protein assay (Pierce ™ BCA Protein Assay Kit, Thermo Fisher Scientific) using BSA
as a standard. Protein sequences were confirmed by LC–MS (Supplementary Figure S2,
Table S3).
5.5. ELISA Binding Assays
Flat-bottomed 96-well plates (Nunc MaxiSorp™, Invitrogen, Thermo Fisher Scientific)
were coated with either 10 µg/mL fetuin in 1× PBS or 0.15 µM GM1 in DMSO + 1× PBS.
Plates were incubated overnight at room temperature. After washing and blocking plates
for 1 h in blocking buffer (1% skim milk powder + 0.05% Tween-20), the toxins CT (List
Biological Labs, Inc., Campbell, CA, USA) or ArtABHIS were added to the first well at a
concentration of 20 µg/mL or 10 µg/mL. Serial two-fold dilutions into blocking buffer were
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performed and plates were incubated for 2 h at 37 ◦ C. After washing, rabbit anti-6XHIS
antibodies (Bethyl Laboratories, Inc., Montgomery, TX, USA) or rabbit anti-CT antibodies
(Sigma-Aldrich, St. Louis, MO, USA) were added at 1:5000 dilution and incubated at
37 ◦ C for 1 h. After washing, goat anti-rabbit HRP-conjugated antibodies (Pierce® , Thermo
Fisher Scientific) were added and incubated at 37 ◦ C for 1 h. Plates were developed
with tetramethylbenzidine (TMB) (PromegaTM TMB One, Thermo Fisher Scientific) and
read at 370 nm per TMB manufacturer’s instructions using a BioTek Cytation 3 imager.
ArtAB ELISAs were compared to the average of a no-toxin negative control coated with
fetuin or GM1 and using anti-6XHIS antibody. Titers were defined as the reciprocal of the
highest dilution at a 370 nm absorbance cut off of 0.2. Titers represent the averages of four
independent assays performed in triplicate for ArtAB, or the average of four independent
assays for CT.
5.6. Cell Culture
African green monkey kidney (Vero; ATCC, Manassas, VA, USA) cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Corning®, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS; HyClone™, Thermo Fisher Scientific), or bovine
growth serum (BGS; HyClone™, Thermo Fisher Scientific) and 1% penicillin/streptomycin
(Thermo Fisher Scientific). CHO-K1 cells (CHO; ATCC® ) were cultured in Ham’s F-12
medium (Corning® , Thermo Fisher Scientific) supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were maintained in T-flasks at 37 ◦ C in a humidified 5% CO2
incubator and were passaged at 80% confluency using 0.05% trypsin/EDTA. Serum-free
cell starvation procedures were completed with media (DMEM for Vero cells, Ham’s F-12
for CHO-K1 cells) supplemented with 1% penicillin/streptomycin but without FBS/BGS.
5.7. Fluorescence Microscopy
Internalization assays were performed as described [67]. Briefly, Vero cells were grown
48 h to subconfluence on uncoated coverslips at 37 ◦ C with 5% CO2 . Cells were maintained
in DMEM containing 4 mM L-glutamine, 4500 mg/L glucose, 10% BGS, 100 IU/mL
penicillin, and 100 µg/mL streptomycin (DMEM+10). Cells were washed with 1× PBS,
then incubated for 15 min at 4 ◦ C, prior to the addition of 50 µg/mL purified ArtABHIS
(from E. coli ClearColi® + pBM003) or PBS negative control. One half of the cells, including
the PBS control, were then shifted to 37 ◦ C for 45 min while the other half remained at
4 ◦ C. Cells were washed, fixed, permeabilized, and blocked for 15 h in 10% BGS at 4 ◦ C.
Cells were then incubated withmouse monoclonal anti-6XHIS (α-HIS, HIS.H8; 1:5000
Abcam, Cambridge, MA, USA) and FITC-conjugated anti-mouse IgG (Sigma-Aldrich)
antibodies. Coverslips were washed and mounted with hard-set mounting medium with
DAPI (Vector Laboratories, Burlingame, CA, USA) before visualization using a Zeiss LSM
510 META laser scanning confocal microscope. Images were acquired using a 100× Alpha
Plan-Fluar 1.45 oil DIC objective, a factory set diode laser for DAPI (405 nm), and an argon
laser for FITC (488 nm). Image acquisition and processing was performed using the LSM
510 META software. All confocal and image settings were held constant between samples
for comparison. Images are representative of at least two fields from one independent assay.
5.8. Cellular Activity and Morphology Assays
Cellular activity was assessed using alamarBlue™ and crystal violet assays. 96-well
plates were seeded with Vero or CHO-K1 cells at a density of 5000 cells per well in 200 µL
of complete culture media and incubated overnight. Cells were starved in serum-free
media for 4 h prior to treatment. ArtAB, or ArtB, in a buffer of 1× PBS + 5% glycerol at
a concentration of 10 µg/mL (2 µg total in 200 µL), 25 µg/mL (5 µg total in 200 µL), or
50 µg/mL (10 µg total in 200 µL); or CT (List Biological Labs, Inc) in a buffer of 1× PBS at
a concentration of 10 µg/mL (2 µg total in 200 µL); or PT (List Biological Labs, Inc.) in a
buffer of 1× PBS at a concentration of 10 µg/mL (2 µg total in 200 µL); or respective buffer
alone (vehicle) in complete culture media was added to the cells. Each treatment was added
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to 6 wells per plate. One replicate included an individual plate for each of four post-dose
time points. Plates for one replicate were treated at the same time, incubated, and removed
from the incubator at the appropriate time point (4, 24, 48, or 72 h post-treatment) for
analysis. Three replicates each were completed on Vero cells and CHO-K1 cells. Statistical
analysis was completed on one representative replicate (plate) for each cell line (n = 6).
After 4, 24, 48, or 72 h of incubation with treatment, brightfield microscopy images at
20× magnification were collected using a BioTek Cytation 3 imager. Images were collected
randomly from varied locations within wells and from multiple wells for each treatment
dose. Immediately after imaging, 200 µL of 10% (v/v) alamarBlue™ (Invitrogen™) in complete culture media was added to each well and plates were incubated for 4 h. Fluorescence
was read on the BioTek Cytation 3 imager using excitation wavelength of 560 nm and
emission wavelength of 590 nm per AlamarBlue™ manufacturer’s instructions. Light
microscopy image files were analyzed using ImageJ Download for Mac OS X. Available
online: https://imagej.nih.gov/ij/download.html (Accessed on 22 July 2021). For each
image, scale was set according to the pixel:length relationship of the scale bar. Cell length
was measured on adherent cells only with a line drawn between the two most distant edges
and centered through the middle of the cell body. Dendrites were followed as long as the
line could be kept centered in the cell body. Measurements were collected for ten cells in
each of three or four frames where each frame represented an independent well for a total
of 30 measurements per treatment group.
After collection of fluorescence data, alamarBlue™ and media were removed and
cells were rinsed 3 times with 200 µL 1× PBS. Crystal violet assays were performed per
Cold Spring Harbor Protocols [40]. Briefly, 50 µL of crystal violet solution was added to
each well and the plates were incubated for 20 min at room temperature with agitation
on an orbital shaker. Crystal violet solution was removed and the cells were rinsed 3
times with deionized water with care given not to lift cells from the plates. Plates were air
dried overnight. The next day, 100 µL methanol was added to each well and the plate was
incubated for 20 min at room temperature with agitation on an orbital shaker. Absorbance
at 570 nm was read on the BioTek Cytation 3 imager.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/toxins13090599/s1, Figure S1: Full-length and truncated artAB on different Salmonella
serovars. Figure S2: Purification of ArtABHIS from E. coli, and sequencing of ArtB-HIS and native
ArtA; Figure S3: Cellular effects of PT on CHO cells; Figure S4: Cell length measurements; Table S1:
Protein accession numbers for phylogenetic analysis; Table S2: LC–MS protein identification.
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